Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

SC Pharmaceuticals Inc (SCPH)

SC Pharmaceuticals Inc (SCPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,359
  • Shares Outstanding, K 36,054
  • Annual Sales, $ 13,590 K
  • Annual Income, $ -54,810 K
  • 60-Month Beta 0.06
  • Price/Sales 12.39
  • Price/Cash Flow N/A
  • Price/Book 4.68
Trade SCPH with:

Options Overview Details

View History
  • Implied Volatility 306.69% ( +77.24%)
  • Historical Volatility 63.83%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 306.69% on 04/18/24
  • IV Low 47.32% on 01/02/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 2,806
  • Open Int (30-Day) 3,021

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.39
  • Low Estimate -0.51
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.25 +6.12%
on 04/18/24
5.70 -20.88%
on 03/21/24
-0.98 (-17.85%)
since 03/18/24
3-Month
4.25 +6.12%
on 04/18/24
6.54 -31.04%
on 02/27/24
-1.25 (-21.70%)
since 01/18/24
52-Week
4.25 +6.12%
on 04/18/24
12.75 -64.63%
on 05/11/23
-5.94 (-56.86%)
since 04/18/23

Most Recent Stories

More News
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SCPH : 4.51 (+2.04%)
CARA : 0.6900 (-5.72%)
Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why

scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...

SCPH : 4.51 (+2.04%)
scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why

scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...

SCPH : 4.51 (+2.04%)
What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock

scPharmaceuticals, Inc. (SCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SCPH : 4.51 (+2.04%)
Wall Street Analysts See a 164% Upside in scPharmaceuticals, Inc. (SCPH): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 163.7% in scPharmaceuticals, Inc. (SCPH). While the effectiveness of this highly sought-after metric is questionable,...

SCPH : 4.51 (+2.04%)
Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?

Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

SCPH : 4.51 (+2.04%)
SNDX : 20.49 (-1.21%)
Pre-Market Brief: Stocks Rebound As Bond Yields Fall, China’s COVID Spike Remains In Focus

December S&P 500 futures (ESZ22) are trending up +0.23% this morning after three major US benchmark indices ended Monday roughly down as market participants remained cautious after reports suggested China...

ESZ22 : 3,871.47s (-0.66%)
ZM : 59.94 (+1.46%)
MULN : 2.91 (+1.04%)
LYFT : 16.71 (-3.47%)
SYM : 40.09 (-4.46%)
A : 132.44 (-1.57%)
SCPH : 4.51 (+2.04%)
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval

scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.

ACAD : 17.07 (-0.70%)
SCPH : 4.51 (+2.04%)
ARDS : 0.0615 (-6.82%)
IMCR : 54.74 (+0.29%)
scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance...

SCPH : 4.51 (+2.04%)
scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

BURLINGTON, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...

SCPH : 4.51 (+2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company's pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via...

See More

Key Turning Points

3rd Resistance Point 4.87
2nd Resistance Point 4.70
1st Resistance Point 4.60
Last Price 4.51
1st Support Level 4.33
2nd Support Level 4.16
3rd Support Level 4.06

See More

52-Week High 12.75
Fibonacci 61.8% 9.50
Fibonacci 50% 8.50
Fibonacci 38.2% 7.50
Last Price 4.51
52-Week Low 4.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar